Table 3 Cancer immunotherapy with additional nucleotide-metabolic targets versus immunotherapy monotherapy in the clinical trials
From: Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy
Therapeutic agents | Therapeutic targets | Accompanied immunotherapy | Participants | ClinicalTrials.gov identifier | Phase | Status |
|---|---|---|---|---|---|---|
Oleclumab | CD73 | Durvalumab | Triple negative breast cancer | NCT03616886 | Phase I/II | Recruiting |
ASOs | CD39 | Durvalumab | Diffuse Large B-cell Lymphoma | NCT02549651 | Phase I | Completed |
Gemcitabine | Ribonucleoside-diphosphate reductase, thymidylate synthase, UMP-CMP kinase | Tislelizumab | Urothelial carcinoma | NCT04570410 | Phase II | Recruiting |
| Â | Â | Durvalumab | Advanced solid tumors | NCT03907475 | Phase II | Recruiting |
Pemetrexed | Thymidylate synthase, bifunctional purine biosynthesis | Pembrolizumab | NSCLC | NCT04533451 | Phase II | Recruiting |
| Â | Â | Pembrolizumab | NSCLC | NCT04547504 | Phase III | Recruiting |
Gemcitabine and 5-FU | Thymidylate synthase | Cabiralizumab and nivolumab | Advanced pancreatic cancer | NCT03336216 | Phase II | Active, not recruiting |
Pemetrexed/ Gemcitabine | Thymidylate synthase | Sintilimab | NSCLC | NCT04728724 | Phase II | Not yet recruiting |
Capecitabine | Thymidylate synthase | Zanidatamab | Her2-expressing cancers | NCT02892123 | Phase I | Recruiting |
| Â | Â | Interferon and interleukin | Advanced renal cell carcinoma | NCT00311467 | Phase III | Terminated |
Azacitidine | Cysteine and methionine metabolism | Pembrolizumab | Metastatic cancer | NCT02959437 | Phase I/II | Completed |
| Â | Â | Anti-OX40 antibody | AML | NCT03390296 | Phase I/II | Recruiting |
Cytarabine | DNA polymerase | Gemtuzumab | AML | NCT00006265 | Phase II | Completed |
| Â | Â | NY-ESO-1T Cells | Synovial Sarcoma | NCT01343043 | Phase I | Completed |
| Â | Â | Autologous HER2-specific T cells | Advanced sarcoma | NCT00902044 | Phase I | Active, not recruiting |
| Â | Â | Personalized neoantigen adoptive cell therapy | Solid tumors | NCT04596033 | Phase I | Recruiting |
| Â | Â | DNR.NPC-specific T cells | Nasopharyngeal carcinoma | NCT02065362 | Phase I | Active, not recruiting |
Dacarbazine | DNA synthesis | CPG 7909 | Melanoma | NCT00070642 | Phase II | Completed |
| Â | Â | Melan-A | Melanoma | NCT00559026 | Phase I | Completed |
Decitabine | DNA (cytosine-5)-methyltransferase 3A and 3B | Nivolumab | NSCLC | NCT02664181 | Phase II | Active, not recruiting |
Idelalisib | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit | Pembrolizumab | CLL and non-Hodgkin lymphoma | NCT02332980 | Phase II | Recruiting |